Acta Scientific Clinical Case Reports

Review ArticleVolume 2 Issue 8


Neeraj Vinayakumar1*, Meenakshi C Nayanar2 and K R Vinayakumar3

1Consultant Gastroenterologist, SriRamakrishna Ashrama Charitable Hospital, Sasthamangalam, Thiruvananthapuram, Kerala, India
2Consultant Paediatrician, Dr V C Nayanar Memorial Hospital, Payyanur, Kerala, India
3Professor, Department of Gastroenterology, Ananthapuri Hospitals and Research Institute, Chackai, Thiruvananthapuram, Kerala, India

*Corresponding Author: Neeraj Vinayakumar, Consultant Gastroenterologist, SriRamakrishna Ashrama Charitable Hospital, Sasthamangalam, Thiruvananthapuram, Kerala, India.

Received: June 08, 2021; Published: July 17, 2021

Citation: Neeraj Vinayakumar., et al. “Mucormycosis". Acta Scientific Clinical Case Reports 2.7 (2021): 32-38.


  Mucormycosis is a rare fungal infection that is seen predominantly in immunosuppressed individuals. There has been an upsurge of cases during the COVID-19 pandemic. Iron plays a vital role in the pathogenesis. The disease may manifest in various types. Globally, the most common form is rhino orbito cerebral mucormycosis (ROCM). The fungi can cause angioinvasion and tissue necrosis. Early diagnosis, surgical debridement and prompt initiation of appropriate anti-fungal therapy plays an important part in determining the course of illness. The mortality rate ranges from 28 - 52%.

Keywords: Mucormycosis; Immunosuppression; COVID-19; Iron; Angioinvasion; Mortality


  1. Petrikkos G., et al. “Epidemiology and Clinical Manifestations of Mucormycosis”. Clinical Infectious Diseases1 (2012): S23-34.
  2. Aiyar Y., et al. “India’s resurgence of COVID-19: urgent actions needed”. The Lancet (2021).
  3. Kwon-Chung KJ. “Taxonomy of Fungi Causing Mucormycosis and Entomophthoramycosis (Zygomycosis) and Nomenclature of the Disease: Molecular Mycologic Perspectives”. Clinical Infectious Diseases1 (2012): S8-15.
  4. Prakash H and Chakrabarti A. “Global Epidemiology of Mucormycosis”. Journal of Fungi1 (2019): 26.
  5. Prakash H and Chakrabarti A. “Epidemiology of Mucormycosis in India”. Microorganisms3 (2021): 523.
  6. Mycosis mucorina (2021).
  7. Clinical presentation of zygomycosis - Mantadakis - 2009 - Clinical Microbiology and Infection - Wiley Online Library (2021).
  8. Chakrabarti A and Dhaliwal M. “Epidemiology of Mucormycosis in India”. Current Fungal Infection Reports4 (2013): 287-292.
  9. Jeong W., et al. “The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports”. Clinical Microbiology and Infection1 (2019): 26-34.
  10. Prakash H., et al. “A prospective multicenter study on mucormycosis in India: Epidemiology, diagnosis, and treatment”. Medical Mycology4 (2019): 395-402.
  11. Szarpak L., et al. “Mucormycosis—A serious threat in the COVID-19 pandemic?” Journal of Infection (2021).
  12. Gamaletsou MN., et al. “Rhino-Orbital-Cerebral Mucormycosis”. Current Infectious Disease Reports4 (2012): 423-434.
  13. Serris A., et al. “Disease Entities in Mucormycosis”. Journal of Fungi1 (2019): 23.
  14. Reid G., et al. “Mucormycosis”. Seminars in Respiratory and Critical Care Medicine1 (2020): 99-114.
  15. Cornely OA., et al. “Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium”. The Lancet Infectious Diseases 12 (2019): e405-421.
  16. Kontoyiannis DP., et al. “Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: a retrospective study”. BMC Infectious Diseases 1 (2016): 730.
  17. Kontoyiannis DP and Lewis RE. “How I treat mucormycosis”. Blood5 (2011): 1216-1224.
  18. Larcher G., et al. “Siderophore Production by Pathogenic Mucorales and Uptake of Deferoxamine B”. Mycopathologia5 (2013): 319-328.
  19. Mucormycosis in India: unique features - Chakrabarti - 2014 - Mycoses - Wiley Online Library (2021).
  20. Patel AK., et al. “Mucormycosis at a tertiary care centre in Gujarat, India”. Mycoses6 (2017): 407-411.
  21. Rise of the phoenix: Mucormycosis in COVID-19 times: Indian Journal of Ophthalmology (2021).
  22. Singh AK., et al. “Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India”. Diabetes and Metabolic Syndrome: Clinical Research and Reviews (2021).
  23. Xu B., et al. “Suppressed T cell-mediated immunity in patients with COVID-19: A clinical retrospective study in Wuhan, China”. Journal of Infection1 (2020): e51-60.
  24. Sarkar S., et al. “COVID-19 and orbital mucormycosis”. Indian Journal of Ophthalmology4 (2021): 1002-1004.
  25. Ibrahim AS and Kontoyiannis DP. “Update on mucormycosis pathogenesis”. Current Opinion in Infectious Diseases - LWW Journals 6 (2013): 508-515.
  26. Ibrahim AS., et al. “The high affinity iron permease is a key virulence factor required for Rhizopus oryzae pathogenesis”. Molecular Microbiology3 (2010): 587-604.
  27. Petrikkos G and Tsioutis C. “Recent Advances in the Pathogenesis of Mucormycoses”. Clinical Therapeutics6 (2018): 894-902.
  28. Danion F., et al. “Mucormycosis: New Developments into a Persistently Devastating Infection”. Seminars in Respiratory and Critical Care Medicine5 (2015): 692-705.
  29. Liu M., et al. “The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice”. Journal of Clinical Investigation6 (2010): 1914-1924.
  30. Zhang L-H and Zhang X. “Roles of GRP78 in physiology and cancer”. Journal of Cellular Biochemistry6 (2010): 1299-1305.
  31. Generation of chemotactic factors by Rhizopus oryzae in the presence and absence of serum: relationship to hyphal damage mediated by human neutrophils and effects of hyperglycemia and ketoacidosis (2021).
  32. Montaño DE and Voigt K. “Host Immune Defense upon Fungal Infections with Mucorales: Pathogen-Immune Cell Interactions as Drivers of Inflammatory Responses”. Journal of Fungi3 (2020): 173.
  33. Prasad BS., et al. “Primary gastrointestinal mucormycosis in an immunocompetent person”. Journal of Postgraduate Medicine3 (2008): 211.
  34. Chayakulkeeree M., et al. “Zygomycosis: the re-emerging fungal infection”. European Journal of Clinical Microbiology and Infectious Diseases4 (2006): 215-229.
  35. Richardson MD and Warnock DW. “Fungal Infection: Diagnosis and Management”. John Wiley and Sons (2012): 481.
  36. Spellberg B., et al. “Novel Perspectives on Mucormycosis: Pathophysiology, Presentation, and Management”. Clinical Microbiology Reviews3 (2005): 556-569.
  37. Improved Outcome of Zygomycosis in Patients with Hematological Diseases?: Leukemia and Lymphoma 45.7 (2021).
  38. Jaju MR., et al. “Different types of mucormycosis: case series (2020).
  39. Costa-Paz M., et al. “Mucormycosis osteomyelitis after anterior cruciate ligament reconstruction”. Bone and Joint Open1 (2021): 3-8.
  40. Quraishi AHM., et al. “Perforation Peritonitis Secondary to Intestinal Mucormycosis in a Boy with Type I Diabetes Mellitus”. Journal of Indian Association of Pediatric Surgeons 2 (2020): 118-120.
  41. Ranjani S., et al. “A case of successful treatment of mucor pyelonephritis in a child with acute lymphoblastic leukemia”. Indian Journal of Case Reports 20 (2018): 109-111.
  42. Bosken Ch., et al. “Superior vena cava syndrome due to mucormycosis in a patient with lymphoma”. Super Vena Cava Syndr Due Mucormycosis Patient Lymphoma 54.6 (1987): 508-511.
  43. A49 Pulmonary Infections: Case Studies (Fungal And Other): A Rare Case Of Bilateral Vocalcord Mucormycosis - ProQuest (2021).
  44. Kataria SP., et al. “Primary breast mucormycosis: FNAC diagnosis of a rare entity”. Diagnostic Cytopathology9 (2016): 761-763.
  45. Biniyam K., et al. “Asymptomatic mucormycosis of middle ear: An incidental finding during tympanoplasty”. Indian Journal of Otology2 (2014): 83.
  46. Shah K and Nene A. “Spinal Mucormycosis”. Journal of Global Infectious Diseases4 (2017): 160-161.
  47. Kung VL., et al. “Diagnostic accuracy of fungal identification in histopathology and cytopathology specimens”. European Journal of Clinical Microbiology and Infectious Diseases1 (2018): 157-165.
  48. Mucocutaneous Splendore‐Hoeppli phenomenon - Hussein - 2008 - Journal of Cutaneous Pathology - Wiley Online Library (2021).
  49. Jenks JD., et al. “Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy”. Drug Design, Development and Therapy 12 (2018): 1033-1044.
  50. Chander J., et al. “Mucormycosis: Battle with the Deadly Enemy over a Five-Year Period in India”. Journal of Fungi2 (2018): 46.
  51. Tragiannidis A and Groll AH. “Hyperbaric oxygen therapy and other adjunctive treatments for zygomycosis”. Clinical Microbiology and Infection5 (2009): 82-86.
  52. Spellberg B and Ibrahim AS. “Recent Advances in the Treatment of Mucormycosis”. Current Infectious Disease Reports6 (2010): 423-429.
  53. Roden MM., et al. “Epidemiology and Outcome of Zygomycosis: A Review of 929 Reported Cases”. Clinical Infectious Diseases5 (2005): 634-653.

Copyright: © 2021 Neeraj Vinayakumar., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is May 30, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US